LCTX vs TEL · rev $9.5M vs P/E 39, rev $17.26B
Lineage Cell Therapeutics Inc (LCTX) versus TE Connectivity Ltd (TEL) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
TE Connectivity Ltd (TEL) is a electronic components company listed on US.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
Latest reported TEL revenue for 2025-09-26 was $17.26B. Net income was $1.84B. Revenue was up 8.9% from 2024-09-27 to 2025-09-26. TEL currently screens at market cap $52.52B and trailing P/E 38.5.
LCTX currently screens at market cap $213.6M. TEL currently screens at market cap $52.52B and trailing P/E 38.5.
Not investment advice. Open the LCTX and TEL stock pages for the full models.
Not investment advice.